New perfusion technologies and AI-driven controls are accelerating adoption across commercial biologics manufacturing.

Cellular and gene therapies have become established treatment options for hematological diseases, including rare and aggressive neoplasms. The clinical ...

In a paper published in Proceedings of the National Academy of Sciences, researchers from Technion and Tel Aviv University ...

Regencell Bioscience Holdings Limited (RGC) focuses on TCM-based treatments for ADHD and Autism, targeting significant ...

German engineering company GEA is relocating its Application and Technology Center for future food from Hildesheim to ...

Candel Therapeutics (CADL) shifts to late-stage oncology with CAN-2409 Phase III wins and BLA catalyst. Read here for a ...

Healthcare veteran Dr Douglas Williams discusses the impact of recent political upheaval in the US and the prospect of major ...

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager ...

Researchers at the University of Bayreuth and Forschungszentrum Jülich have demonstrated that specific light-sensitive ...

Biotech companies are spending billions to perfect chemical formulas, only to be tripped up by the one variable they forgot ...

Pierre-Alain Ruffieux of Cytiva discusses key biotech trends including new modalities, AI adoption, supply chain stability, ...

We spoke to David Klenerman, co-developer of sequencing by synthesis, to find out how his work heralded the next generation ...